Last updated: February 29, 2024
Sponsor: Hospital Clinico Universitario de Santiago
Overall Status: Active - Recruiting
Phase
N/A
Condition
Respiratory Syncytial Virus (Rsv) Infection
Asthma
Respiratory Syncytial Virus (Rsv)
Treatment
PCR
Clinical Study ID
NCT06286007
PRIPASCO-2023
Ages 18-99 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Adult patient (age 18 years and over)
- Diagnosed with asthma at least one year prior to the date of enrolment.
- Patients who, in the opinion of the investigator, can and will comply with therequirements of the study protocol for the duration of the follow-up period (e.g.agree to provide samples for testing, able to attend for testing upon asthmaexacerbation and/or ARI symptoms occurring)
- Patients who are able to provide written informed consent.
Exclusion
Exclusion Criteria:
- Patients with a prior history of pertussis in the last 12 months
- Patients with ARI within the 2 weeks prior to enrolment
- Patients who have another respiratory disease other than asthma, alcohol or drug abuseat the time of being included in the study, or an active oncological disease (patientsin treatment or follow-up for oncological disease) or pregnant women.
- Patients treated with immunosuppressive or immunomodulating agents not related toasthma diagnosis. will be excluded.
- Patients vaccinated for RSV will be also excluded (NOTE: -Patients that have receivedan RSV (investigational) vaccine or medicine for any of the above, should be excludedfrom the study from the beginning. Patients that might be vaccinated in the upcomingyears, while the study is still ongoing, can enrol. However, from the moment theyreceive a vaccine, they should be excluded and no additional data will be collected.Data collected during the study up until the time of vaccination will still beincluded in the analysis).
- Patients vaccinated for B. Pertussis during the previous 12 months will be alsoexcluded.
- Patients who plan to move during the study period will be excluded.
Study Design
Total Participants: 784
Treatment Group(s): 1
Primary Treatment: PCR
Phase:
Study Start date:
December 21, 2023
Estimated Completion Date:
July 01, 2026
Study Description
Connect with a study center
Hospital Clínico Universitario de Santiago de Compostela
Santiago De Compostela, A Coruña 15706
SpainActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.